Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response.

Erasmus JJ, Gladish GW, Broemeling L, Sabloff BS, Truong MT, Herbst RS, Munden RF.

J Clin Oncol. 2003 Jul 1;21(13):2574-82.

PMID:
12829678
2.

Effect of the introduction of minimum lesion size on interobserver reproducibility using RECIST guidelines in non-small cell lung cancer patients.

Watanabe H, Kunitoh H, Yamamoto S, Kawasaki S, Inoue A, Hotta K, Shiomi K, Kusumoto M, Sugimura K, Saijo N.

Cancer Sci. 2006 Mar;97(3):214-8.

3.

Volumetric evaluation of therapy response in patients with lung metastases. Preliminary results with a computer system (CAD) and comparison with unidimensional measurements.

Fraioli F, Bertoletti L, Napoli A, Calabrese FA, Masciangelo R, Cortesi E, Catalano C, Passariello R.

Radiol Med. 2006 Apr;111(3):365-75. Epub 2006 Apr 11. English, Italian.

PMID:
16683084
4.

Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy.

Jacene HA, Leboulleux S, Baba S, Chatzifotiadis D, Goudarzi B, Teytelbaum O, Horton KM, Kamel I, Macura KJ, Tsai HL, Kowalski J, Wahl RL.

J Nucl Med. 2009 Nov;50(11):1760-9. doi: 10.2967/jnumed.109.063321. Epub 2009 Oct 16.

5.

Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials.

Schwartz LH, Mazumdar M, Wang L, Smith A, Marion S, Panicek DM, Motzer RJ.

Cancer. 2003 Oct 15;98(8):1611-9.

6.
7.

Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection.

Brooks KR, To K, Joshi MB, Conlon DH, Herndon JE 2nd, D'Amico TA, Harpole DH Jr.

Ann Thorac Surg. 2003 Jul;76(1):187-93; discussion 193.

PMID:
12842538
8.

A statistical simulation study finds discordance between WHO criteria and RECIST guideline.

Mazumdar M, Smith A, Schwartz LH.

J Clin Epidemiol. 2004 Apr;57(4):358-65.

PMID:
15135836
9.

PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes.

van Baardwijk A, Bosmans G, Boersma L, Buijsen J, Wanders S, Hochstenbag M, van Suylen RJ, Dekker A, Dehing-Oberije C, Houben R, Bentzen SM, van Kroonenburgh M, Lambin P, De Ruysscher D.

Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):771-8. Epub 2007 Mar 29.

PMID:
17398018
10.

Response to combined modality therapy correlates with survival in locally advanced non-small-cell lung cancer.

Kim DW, Shyr Y, Chen H, Akerley W, Johnson DH, Choy H.

Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1029-36.

PMID:
15913910
11.

Measuring response in solid tumors: comparison of RECIST and WHO response criteria.

Park JO, Lee SI, Song SY, Kim K, Kim WS, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Lee KS, Park K.

Jpn J Clin Oncol. 2003 Oct;33(10):533-7.

PMID:
14623923
12.

Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria.

Krajewski KM, Nishino M, Franchetti Y, Ramaiya NH, Van den Abbeele AD, Choueiri TK.

Cancer. 2014 Mar 1;120(5):711-21. doi: 10.1002/cncr.28493. Epub 2013 Nov 21.

13.

Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria.

Suzuki C, Torkzad MR, Jacobsson H, Aström G, Sundin A, Hatschek T, Fujii H, Blomqvist L.

Acta Oncol. 2010 May;49(4):509-14. doi: 10.3109/02841861003705794.

PMID:
20397778
14.

Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy.

Pöttgen C, Levegrün S, Theegarten D, Marnitz S, Grehl S, Pink R, Eberhardt W, Stamatis G, Gauler T, Antoch G, Bockisch A, Stuschke M.

Clin Cancer Res. 2006 Jan 1;12(1):97-106.

15.

Reliability and agreement between fine-cut CT scans and plain radiography in the evaluation of posterolateral fusions.

Carreon LY, Glassman SD, Djurasovic M.

Spine J. 2007 Jan-Feb;7(1):39-43. Epub 2006 Nov 20.

PMID:
17197331
16.

Basic fibroblast growth factor-2/beta3 integrin expression profile: signature of local progression after chemoradiotherapy for patients with locally advanced non-small-cell lung cancer.

Massabeau C, Rouquette I, Lauwers-Cances V, Mazières J, Bachaud JM, Armand JP, Delisle MB, Favre G, Toulas C, Cohen-Jonathan-Moyal E.

Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):696-702. doi: 10.1016/j.ijrobp.2008.11.050. Epub 2009 Apr 20.

PMID:
19386436
17.

FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer.

Ohtsuka T, Nomori H, Ebihara A, Watanabe K, Kaji M, Naruke T, Suemasu K, Uno K.

Ann Thorac Cardiovasc Surg. 2006 Apr;12(2):89-94.

PMID:
16702929
18.

Volumetrical measurements in vestibular schwannoma, the influence of slice thickness and patient's repositioning.

Luppino FS, Grooters E, de Bruïne FT, Zwinderman AH, van der Mey AG.

Otol Neurotol. 2006 Oct;27(7):962-8.

PMID:
17006347
19.

Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response.

Pourel N, Santelmo N, Naafa N, Serre A, Hilgers W, Mineur L, Molinari N, Reboul F.

Eur J Cardiothorac Surg. 2008 May;33(5):829-36. doi: 10.1016/j.ejcts.2008.01.063. Epub 2008 Mar 25.

PMID:
18367406
20.

Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study.

Zatloukal P, Petruzelka L, Zemanova M, Havel L, Janku F, Judas L, Kubik A, Krepela E, Fiala P, Pecen L.

Lung Cancer. 2004 Oct;46(1):87-98.

PMID:
15364136

Supplemental Content

Support Center